Identification

Name
Isosorbide Mononitrate
Accession Number
DB01020  (APRD00528)
Type
Small Molecule
Groups
Approved
Description

Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold by AstraZeneca under the trade name Imdur.

Isosorbide mononitrate is used to for the the prophylactic treatment of angina pectoris; that is, it is taken in order to prevent or at least reduce the occurrence of angina. Research on Isosorbide mononitrate as a cervical ripener to reduce time at hospital to birth is supportive.

Isosorbide mononitrate is an active metabolite of isosorbide dinitrate and exerts qualitatively similar effects. Isosorbide mononitrate reduces the workload of the heart by producing venous and arterial dilation. By reducing the end diastolic pressure and volume, isosorbide mononitrate lowers intramural pressure, hence leading to an improvement in the subendocardial blood flow. The net effect when administering isosorbide mononitrate is therefore a reduced workload for the heart and an improvement in the oxygen supply/demand balance of the myocardium.

The adverse reactions which follow have been reported in studies with isosorbide mononitrate: Very common. Headache predominates (up to 30%) necessitating withdrawal of 2 to 3 % of patients, but the incidence reduces rapidly as treatment continues . Common. Tiredness, sleep disturbances (6%) and gastrointestinal disturbances (6%) have been reported during clinical trials with isosorbide mononitrate modified release tablets, but at a frequency no greater than for placebo. Hypotension (4 to 5%), poor appetite (2.5%), nausea (1%). Adverse effects associated with the clinical use of the drug are as expected with all nitrate preparations. They occur mainly in the early stages of treatment. Hypotension (4%) with symptoms such as dizziness and nausea (1%) have been reported. These symptoms generally disappear during long-term treatment. Other reactions that have been reported with isosorbide mononitrate modified release tablets include tachycardia, vomiting, diarrhoea, vertigo and heartburn

Structure
Thumb
Synonyms
  • IS 5-MN
  • IS-5-MN
  • IS-5MN
  • ISMN
  • Iso-5-mononitrate
  • Isosorbide 5-mononitrate
  • Isosorbide 5-nitrate
  • Isosorbide-5-mononitrate
  • isosorbidi mononitras
  • mononitrate d'isosorbide
  • mononitrato de isosorbida
  • Monosorbitrate
External IDs
AHR-4698 / BM 22.145 / BM-22.145 / BM-22145
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-ismnTablet, extended release60 mgOralDominion PharmacalNot applicableNot applicableCanada
Imdur - Extended Release Tablets 60 mgTablet, extended release60 mgOralAstra Zeneca1994-12-31Not applicableCanada
IsmnTablet, extended release60 mgOralSivem Pharmaceuticals Ulc2015-10-082017-06-27Canada
Ismo Tab 20mgTablet20 mgOralWyeth Ayerst Canada Inc.1994-12-312002-06-10Canada
Isosorbide MononitrateTablet10 mg/1OralPhysicians Total Care, Inc.2012-07-18Not applicableUs
Isosorbide MononitrateTablet10 mg/1OralKremers Urban1993-06-30Not applicableUs62175 0106 01 nlmimage10 15460ad0
Isosorbide MononitrateTablet20 mg/1OralCarilion Materials Management1993-06-30Not applicableUs
Isosorbide MononitrateTablet20 mg/1OralProficient Rx LP1993-06-30Not applicableUs
Isosorbide MononitrateTablet20 mg/1OralKremers Urban1993-06-30Not applicableUs62175 0107 01 nlmimage10 7f083fd1
MonoketTablet20 mg/1OralKremers Urban1993-06-30Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ismnTablet, extended release60 mgOralApotex Corporation2006-03-03Not applicableCanada
ImdurTablet, extended release120 mg/1OralSchering Corporation2006-01-052017-08-05Us
ImdurTablet, extended release60 mg/1OralSchering Corporation2006-01-052017-08-05Us
ImdurTablet, extended release30 mg/1OralSchering Corporation2006-01-052017-08-05Us
IsosorbideTablet, film coated, extended release60 mg/1OralRemedy Repack2013-05-292017-01-04Us
IsosorbideTablet, film coated, extended release60 mg/1OralWest Ward Pharmaceutical2006-03-30Not applicableUs
IsosorbideTablet, film coated, extended release60 mg/1OralCardinal Health2006-03-302015-12-29Us
IsosorbideTablet, film coated, extended release30 mg/1OralCarilion Materials Management2006-03-30Not applicableUs
IsosorbideTablet, film coated, extended release30 mg/1OralCardinal Health2006-03-302015-12-29Us
IsosorbideTablet, film coated, extended release30 mg/1OralWest Ward Pharmaceutical2006-03-30Not applicableUs
International/Other Brands
Chemydur / Corangin / Dilatrate / Duride / Elantan / Etimonis / Imodur / Imtrate / Ismexin / Ismo / Ismox / Isomon / Isomonit / Isonorm / Medocor / Monicor / Monit / Mono Corax / Mono Mack / Monocedocard / Monoclair / Monocord / Monodur Durules / Monolong / Monomax / Mononit / Monopront / Monosorb / Monosordil / Monotrate / Nitramin / Olicard / Olicardin / Orasorbil / Pertil / Plodin / Promocard / Sigacora / Solotrate / Sorbimon / Turimonit / Uniket / Vasdilat
Categories
UNII
LX1OH63030
CAS number
16051-77-7
Weight
Average: 191.1388
Monoisotopic: 191.042987025
Chemical Formula
C6H9NO6
InChI Key
YWXYYJSYQOXTPL-SLPGGIOYSA-N
InChI
InChI=1S/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1
IUPAC Name
(3R,3aS,6S,6aR)-6-hydroxy-hexahydrofuro[3,2-b]furan-3-yl nitrate
SMILES

Pharmacology

Indication

For the prevention of angina pectoris due to coronary artery disease and the treatment of acute and chronic angina pectoris, hypertension, and myocardial infarction.

Structured Indications
Pharmacodynamics

Isosorbide-5-mononitrate, the long-acting metabolite of isosorbide dinitrate, is used as a vasodilatory agent in the management of angina pectoris. By dilating the vessels, it lowers the blood pressure and reduces the left ventricular preload and afterload, therefore, leads to a reduction of myocardial oxygen requirement.

Mechanism of action

Similar to other nitrites and organic nitrates, Isosorbide Mononitrate is converted to nitric oxide (NO), an active intermediate compound which activates the enzyme guanylate cyclase (Atrial natriuretic peptide receptor A). This stimulates the synthesis of cyclic guanosine 3',5'-monophosphate (cGMP) which then activates a series of protein kinase-dependent phosphorylations in the smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light chain of the smooth muscle fiber. The subsequent release of calcium ions results in the relaxation of the smooth muscle cells and vasodilation.

TargetActionsOrganism
AGuanylate cyclase soluble subunit alpha-2
inducer
Human
Absorption

100%

Volume of distribution
  • 0.6 to 0.7 L/kg
Protein binding

5%

Metabolism

Hepatic

Route of elimination

Isosorbide mononitrate is primarily metabolized by the liver, but unlike oral isosorbide dinitrate, it is not subject to first-pass metabolism. Isosorbide mononitrate is cleared by denitration to isosorbide and glucuronidation as the mononitrate, with 96% of the administered dose excreted in the urine within 5 days and only about 1% eliminated in the feces. At least six different compounds have been detected in urine, with about 2% of the dose excreted as the unchanged drug and at least five metabolites.

Half life

5 hours

Clearance
  • 120–122 mL/min [Single dose of 60 mg PO]
  • 151–187 mL/min [Single dose of extended-release tablet 60 mg PO]
  • 132-151 mL/min [Multiple doses of extended release tablet 60 mg PO]
  • 119-140 mL/min [Multiple doses of extended release tablet 120 mg PO]
Toxicity

Symptoms of overdose include vasodilatation, venous pooling, reduced cardiac output, and hypotension. There are no data suggesting what dose of isosorbide mononitrate is likely to be life-threatening in humans. In rats and mice, there is significant lethality at doses of 2000 mg/kg and 3000 mg/kg, respectively.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Acebutolol.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Isosorbide Mononitrate.Approved
AliskirenThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Aliskiren.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Isosorbide Mononitrate.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Isosorbide Mononitrate.Approved
AmiodaroneThe metabolism of Isosorbide Mononitrate can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Isosorbide Mononitrate.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Isosorbide Mononitrate.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Amyl Nitrite.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Isosorbide Mononitrate.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Isosorbide Mononitrate.Approved
AprepitantThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Isosorbide Mononitrate.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isosorbide Mononitrate.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Isosorbide Mononitrate.Approved, Investigational
AtazanavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Isosorbide Mononitrate.Approved
AtomoxetineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Atomoxetine.Approved
AvanafilAvanafil may increase the vasodilatory activities of Isosorbide Mononitrate.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Azilsartan medoxomil.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Isosorbide Mononitrate.Experimental
BarbitalBarbital may increase the hypotensive activities of Isosorbide Mononitrate.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Isosorbide Mononitrate.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Isosorbide Mononitrate.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Isosorbide Mononitrate.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Isosorbide Mononitrate.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Isosorbide Mononitrate.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Isosorbide Mononitrate.Approved
BoceprevirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Isosorbide Mononitrate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Isosorbide Mononitrate.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Isosorbide Mononitrate.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Isosorbide Mononitrate.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Isosorbide Mononitrate.Approved, Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Isosorbide Mononitrate.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Captopril.Approved
CarbamazepineThe metabolism of Isosorbide Mononitrate can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Isosorbide Mononitrate.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Isosorbide Mononitrate.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Carvedilol.Approved, Investigational
CeritinibThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Ceritinib.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Mononitrate.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Isosorbide Mononitrate.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Isosorbide Mononitrate.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Isosorbide Mononitrate.Approved, Investigational
ClarithromycinThe metabolism of Isosorbide Mononitrate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Isosorbide Mononitrate.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Isosorbide Mononitrate.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Isosorbide Mononitrate.Approved
ClotrimazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Isosorbide Mononitrate.Approved
CobicistatThe metabolism of Isosorbide Mononitrate can be decreased when combined with Cobicistat.Approved
ConivaptanThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Isosorbide Mononitrate can be decreased when combined with Crizotinib.Approved
CyclosporineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Isosorbide Mononitrate.Investigational
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Isosorbide Mononitrate.Approved, Investigational
DarunavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Delavirdine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Isosorbide Mononitrate.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isosorbide Mononitrate.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Diclofenamide.Approved
DihydroergotamineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Isosorbide Mononitrate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Isosorbide Mononitrate.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isosorbide Mononitrate.Approved
DoxycyclineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Isosorbide Mononitrate can be decreased when combined with Dronedarone.Approved
DuloxetineIsosorbide Mononitrate may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Isosorbide Mononitrate.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Isosorbide Mononitrate.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Isosorbide Mononitrate.Approved
EnzalutamideThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Isosorbide Mononitrate.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Isosorbide Mononitrate.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isosorbide Mononitrate.Approved
ErythromycinThe metabolism of Isosorbide Mononitrate can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Isosorbide Mononitrate.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Isosorbide Mononitrate.Approved
EthanolEthanol may increase the vasodilatory activities of Isosorbide Mononitrate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Felodipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Isosorbide Mononitrate.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Isosorbide Mononitrate.Approved, Investigational
FluconazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Fluconazole.Approved
FluvoxamineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Isosorbide Mononitrate.Approved
FosphenytoinThe metabolism of Isosorbide Mononitrate can be increased when combined with Fosphenytoin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Isosorbide Mononitrate.Approved, Vet Approved
Fusidic AcidThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Fusidic Acid.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Isosorbide Mononitrate.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Isosorbide Mononitrate.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
HydralazineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Isosorbide Mononitrate.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Isosorbide Mononitrate.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Isosorbide Mononitrate.Approved, Investigational
ImatinibThe metabolism of Isosorbide Mononitrate can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Isosorbide Mononitrate.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Isosorbide Mononitrate.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Isosorbide Mononitrate.Approved
IndinavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Isosorbide Mononitrate.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Isosorbide Mononitrate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Isosorbide Mononitrate.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Isosorbide Mononitrate.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Isosorbide Mononitrate.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Isosorbide Mononitrate.Approved
ItraconazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Isosorbide Mononitrate.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Isosorbide Mononitrate.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Isosorbide Mononitrate.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Isosorbide Mononitrate.Approved, Investigational
LevodopaIsosorbide Mononitrate may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Isosorbide Mononitrate.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Isosorbide Mononitrate.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Isosorbide Mononitrate.Approved, Investigational
LopinavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Lopinavir.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Isosorbide Mononitrate.Approved
LovastatinThe metabolism of Isosorbide Mononitrate can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Isosorbide Mononitrate can be increased when combined with Lumacaftor.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Isosorbide Mononitrate.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Isosorbide Mononitrate.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Isosorbide Mononitrate.Approved
MethohexitalMethohexital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide Mononitrate.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Isosorbide Mononitrate.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved
MetipranololThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Isosorbide Mononitrate.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isosorbide Mononitrate.Approved, Investigational
MifepristoneThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Mifepristone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Isosorbide Mononitrate.Approved
MirodenafilMirodenafil may increase the vasodilatory activities of Isosorbide Mononitrate.Investigational
MitotaneThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Mitotane.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Isosorbide Mononitrate.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Isosorbide Mononitrate.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Isosorbide Mononitrate.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Isosorbide Mononitrate.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Isosorbide Mononitrate.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nadolol.Approved
NebivololThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Isosorbide Mononitrate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Isosorbide Mononitrate can be increased when combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Isosorbide Mononitrate.Approved
NicorandilNicorandil may increase the hypotensive activities of Isosorbide Mononitrate.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nifedipine.Approved
NilotinibThe metabolism of Isosorbide Mononitrate can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Isosorbide Mononitrate.Approved, Investigational
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Isosorbide Mononitrate.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isosorbide Mononitrate.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Isosorbide Mononitrate.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Isosorbide Mononitrate.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Isosorbide Mononitrate.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Isosorbide Mononitrate.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Isosorbide Mononitrate.Approved
OlaparibThe metabolism of Isosorbide Mononitrate can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isosorbide Mononitrate.Approved, Investigational
OsimertinibThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Osimertinib.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Isosorbide Mononitrate.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Isosorbide Mononitrate.Approved, Vet Approved
PalbociclibThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Palbociclib.Approved
PapaverineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Papaverine.Approved
PenbutololThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Penbutolol.Approved, Investigational
PentobarbitalThe metabolism of Isosorbide Mononitrate can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Isosorbide Mononitrate.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Isosorbide Mononitrate.Approved
PhenobarbitalThe metabolism of Isosorbide Mononitrate can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Isosorbide Mononitrate.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Isosorbide Mononitrate.Approved
PhenytoinThe metabolism of Isosorbide Mononitrate can be increased when combined with Phenytoin.Approved, Vet Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Isosorbide Mononitrate.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Isosorbide Mononitrate.Approved, Investigational
PosaconazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Isosorbide Mononitrate.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Isosorbide Mononitrate.Approved
PrilocaineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Prilocaine.Approved
PrimidoneThe metabolism of Isosorbide Mononitrate can be increased when combined with Primidone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Isosorbide Mononitrate.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Isosorbide Mononitrate.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Isosorbide Mononitrate.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Isosorbide Mononitrate.Approved
RanolazineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Isosorbide Mononitrate.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Isosorbide Mononitrate.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Isosorbide Mononitrate.Approved, Investigational
RifabutinThe metabolism of Isosorbide Mononitrate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Isosorbide Mononitrate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Isosorbide Mononitrate can be increased when combined with Rifapentine.Approved
RiociguatIsosorbide Mononitrate may increase the hypotensive activities of Riociguat.Approved
RisperidoneIsosorbide Mononitrate may increase the hypotensive activities of Risperidone.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Isosorbide Mononitrate.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Isosorbide Mononitrate.Approved
RosiglitazoneThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Isosorbide Mononitrate.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Isosorbide Mononitrate.Approved
SaquinavirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Isosorbide Mononitrate.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Isosorbide Mononitrate.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Isosorbide Mononitrate.Approved, Vet Approved
SildenafilThe metabolism of Isosorbide Mononitrate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Isosorbide Mononitrate.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Isosorbide Mononitrate.Approved
St. John's WortThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Isosorbide Mononitrate can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Isosorbide Mononitrate.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Isosorbide Mononitrate.Approved, Investigational
SulfisoxazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
TadalafilTadalafil may increase the vasodilatory activities of Isosorbide Mononitrate.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Isosorbide Mononitrate.Approved, Investigational
TelaprevirThe metabolism of Isosorbide Mononitrate can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Isosorbide Mononitrate can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Isosorbide Mononitrate.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Terazosin.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Isosorbide Mononitrate.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Isosorbide Mononitrate.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Isosorbide Mononitrate.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Isosorbide Mononitrate.Approved, Withdrawn
TiclopidineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Isosorbide Mononitrate.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Isosorbide Mononitrate.Approved
TocilizumabThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Isosorbide Mononitrate.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Isosorbide Mononitrate.Approved, Withdrawn
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Isosorbide Mononitrate.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Isosorbide Mononitrate.Approved
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isosorbide Mononitrate.Approved
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Isosorbide Mononitrate.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Isosorbide Mononitrate.Approved
UdenafilUdenafil may increase the vasodilatory activities of Isosorbide Mononitrate.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Isosorbide Mononitrate.Approved, Investigational
VardenafilVardenafil may increase the vasodilatory activities of Isosorbide Mononitrate.Approved
VenlafaxineThe metabolism of Isosorbide Mononitrate can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Isosorbide Mononitrate.Approved
VoriconazoleThe metabolism of Isosorbide Mononitrate can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Isosorbide Mononitrate can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Take without regard to meals.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15155
KEGG Drug
D00630
KEGG Compound
C07714
PubChem Compound
27661
PubChem Substance
46506594
ChemSpider
25736
ChEBI
6062
ChEMBL
CHEMBL1311
Therapeutic Targets Database
DAP001058
PharmGKB
PA450126
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Isosorbide_mononitrate
ATC Codes
C01DA14 — Isosorbide mononitrate
AHFS Codes
  • 24:12.08 — Nitrates and Nitrites
FDA label
Download (217 KB)
MSDS
Download (66.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedDiagnosticHigh Blood Pressure (Hypertension)1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHigh Blood Pressure (Hypertension)2
1Not Yet RecruitingTreatmentAnal Fissures1
1RecruitingTreatmentCoronary Artery Disease1
1, 2RecruitingNot AvailableCoronary Microvascular Disease1
2CompletedTreatmentHeart Failure, Unspecified / Preserved Ejection Fraction1
2RecruitingOtherRenal Insufficiency,Chronic1
2RecruitingPreventionCerebral Small Vessels Disease / Cognitive Impairments / Strokes1
2RecruitingTreatmentCervical Ripening1
2RecruitingTreatmentMissed Abortion1
2, 3CompletedTreatmentIsolated (Idiopathic) Oligohydramnios1
3Unknown StatusTreatmentStable Angina (SA)1
4CompletedPreventionHemorrhage, Gastrointestinal / Liver Cirrhosis / Portal Hypertension1
4CompletedPreventionVariceal Rebleeding1
4CompletedTreatmentMyocardial Ischemia / Quality of Life / Stable Angina (SA)1
Not AvailableCompletedTreatmentMigraines1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableNot Yet RecruitingPreventionPreeclampsia / Premature Labour1

Pharmacoeconomics

Manufacturers
  • Schering plough corp
  • Actavis elizabeth llc
  • Brightstone pharma inc
  • Dexcel ltd
  • Elan pharmaceutical research corp
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kremers urban co
  • Kv pharmaceutical co
  • Vintage pharmaceuticals inc
  • West ward pharmaceutical corp
  • Promius pharma llc
  • Teva pharmaceuticals usa inc
  • Schwarz gmbh
Packagers
Dosage forms
FormRouteStrength
Tablet, extended releaseOral120 mg/1
Tablet, extended releaseOral30 mg/1
Tablet, extended releaseOral60 mg/1
Tablet, extended releaseOral60 mg
TabletOral20 mg
Tablet, film coated, extended releaseOral30 mg/1
Tablet, film coated, extended releaseOral60 mg/1
TabletOral10 mg/1
TabletOral120 mg/1
TabletOral20 mg/1
TabletOral30 mg/1
TabletOral60 mg/1
Tablet, coatedOral20 mg/1
Prices
Unit descriptionCostUnit
Imdur er 120 mg tablet4.19USD tablet
Imdur 120 mg 24 Hour tablet3.15USD tablet
Imdur 60 mg 24 Hour tablet3.11USD tablet
Imdur er 60 mg tablet2.99USD tablet
Imdur 30 mg 24 Hour tablet2.87USD tablet
Imdur er 30 mg tablet2.85USD tablet
Monoket 20 mg tablet2.65USD tablet
Ismo 20 mg tablet2.1USD tablet
Monoket 10 mg tablet1.75USD tablet
Isosorbide Mononitrate CR 60 mg 24 Hour tablet1.48USD tablet
Isosorbide Mononitrate CR 30 mg 24 Hour tablet1.16USD tablet
Isosorbide Mononitrate 20 mg tablet0.78USD tablet
Isosorbide Mononitrate 10 mg tablet0.74USD tablet
Imdur 60 mg Extended-Release Tablet0.74USD tablet
Isosorbide mn 20 mg tablet0.72USD tablet
Isosorbide mn 10 mg tablet0.71USD tablet
Apo-Ismn 60 mg Extended-Release Tablet0.42USD tablet
Pms-Ismn 60 mg Extended-Release Tablet0.42USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)88-91 °CNot Available
water solubility1.07E+005 mg/LNot Available
logP-0.15SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility57.0 mg/mLALOGPS
logP-0.74ALOGPS
logP-0.48ChemAxon
logS-0.53ALOGPS
pKa (Strongest Acidic)13.34ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area93.74 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity38.08 m3·mol-1ChemAxon
Polarizability15.85 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier+0.9355
Caco-2 permeable-0.579
P-glycoprotein substrateNon-substrate0.7621
P-glycoprotein inhibitor INon-inhibitor0.7159
P-glycoprotein inhibitor IINon-inhibitor0.9116
Renal organic cation transporterNon-inhibitor0.8563
CYP450 2C9 substrateNon-substrate0.8674
CYP450 2D6 substrateNon-substrate0.8613
CYP450 3A4 substrateSubstrate0.5357
CYP450 1A2 substrateNon-inhibitor0.8532
CYP450 2C9 inhibitorNon-inhibitor0.8769
CYP450 2D6 inhibitorNon-inhibitor0.9106
CYP450 2C19 inhibitorNon-inhibitor0.8469
CYP450 3A4 inhibitorNon-inhibitor0.9471
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9596
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7696
BiodegradationReady biodegradable0.8359
Rat acute toxicity2.0753 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5741
hERG inhibition (predictor II)Non-inhibitor0.9304
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as isosorbides. These are organic polycyclic compounds containing an isosorbide(1,4-Dianhydrosorbitol) moiety, which consists of two -oxolan-3-ol rings.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Furofurans
Sub Class
Isosorbides
Direct Parent
Isosorbides
Alternative Parents
Tetrahydrofurans / Alkyl nitrates / Secondary alcohols / Organic nitro compounds / Organic nitric acids and derivatives / Oxacyclic compounds / Dialkyl ethers / Organic zwitterions / Organic oxides / Organic nitrogen compounds
show 1 more
Substituents
Isosorbide / Organic nitrate / Tetrahydrofuran / Alkyl nitrate / Organic nitric acid or derivatives / Secondary alcohol / Organic nitro compound / Dialkyl ether / Ether / Oxacycle
show 10 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
nitrate ester, glucitol derivative (CHEBI:6062)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inducer
General Function
Heme binding
Specific Function
Has guanylyl cyclase on binding to the beta-1 subunit.Isoform 2 acts as a negative regulator of guanylyl cyclase activity as it forms non-functional heterodimers with the beta subunits.
Gene Name
GUCY1A2
Uniprot ID
P33402
Uniprot Name
Guanylate cyclase soluble subunit alpha-2
Molecular Weight
81749.185 Da
References
  1. Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109-42. [PubMed:1852778]
  2. Mancuso C, Navarra P, Preziosi P: Roles of nitric oxide, carbon monoxide, and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J Neurochem. 2010 May;113(3):563-75. doi: 10.1111/j.1471-4159.2010.06606.x. Epub 2010 Jan 20. [PubMed:20089135]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18